Drug Trial Radar · NCT06497140
Effect of Genicular Arteries Embolization in Symptomatic Knee Osteoarthritis LipioJoint-2
Last checked: Nov 20, 2026Latest source record: Oct 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
130
Planned (sponsor's estimate)
Start
Sep 30, 2024
Primary completion
Jan 1, 2028
Study completion Oct 1, 2028
Sponsor
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Ministry of Health, France
- First posted
- Jul 11, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Knee OsteoArthritis (KOA) is a common disease associated with pain and impaired function. Many patients are not relieved of their symptoms with enough efficacy by conservative treatments. Genicular Arteries Embolization (GAE) is a new minimally invasive endovascular treatment allowing symptoms relief. The investigator previously demonstrated the safety of GAE using an ethiodized oil-based emulsion for the treatment of painful knee osteoarthritis in a first-in-man single-arm clinical trial called LipioJoint-1 (clinicaltrials.gov: NCT04733092; EUDRACT: 2020-002206-10). This phase 1 study also provided encouraging evidence of GAE efficacy on knee pain and function. The purpose of LipioJoint-2 study is to assess GAE efficacy using an ethiodized oil-based emulsion for the treatment of painful knee osteoarthritis in a multicenter, prospective, randomized sham-controlled clinical trial.
Conditions
- Knee Osteoarthritis
Interventions
Ethiodized Oil-based emulsionDrug
Embolization of genicular arteries
Sham-operationProcedure
Mimicked catheterization and embolization of genicular arteries
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change of pain assessed by a Visual Analogue Scale (VAS) at 3 months compared to randomization.Time frame: 3 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Hôpital Saint Antoine - APHP
Paris, France · Recruiting
Hôpital Cochin - APHP
Paris, France · Recruiting
Hôpital européen Georges Pomidou - APHP
Paris, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.